Literature DB >> 3052011

Retransplantation for severe accelerated coronary artery disease in heart transplant recipients.

S Z Gao1, J S Schroeder, S Hunt, E B Stinson.   

Abstract

Development of accelerated coronary artery disease (CAD) in the cardiac allograft is one of the major causes of late graft failure in heart transplant recipients. At the Stanford University Medical Center 356 heart transplant procedures were performed in 329 patients by the end of January 1985. Eighty-nine of these patients developed evidence of transplant CAD. Twenty retransplant procedures, including 2 third transplants, were performed in 19 of the 89 patients because of transplant CAD. The graft survival rates after the second transplant were 55%, 25% and 10% after 1, 2 and 5 years, respectively. Nine of these retransplant patients currently survive, the longest for 5.5 years. To examine potential risk factors for development of severe transplant CAD, these 20 retransplant procedures were compared with 113 transplant recipients who had no evidence of transplant CAD on annual coronary arteriograms. An excess of rejection episodes (3 +/- 2 vs 2 +/- 1 episodes/patient, p = 0.02), elevated total cholesterol (266 +/- 78 vs 225 +/- 47 mg/dl, p = 0.002) and higher low-density lipoprotein levels (176 +/- 88 vs 137 +/- 46 mg/dl, p = 0.009) were noted in the transplant CAD retransplant group. Five of 11 retransplant recipients who survived greater than 1 year again developed transplant CAD. Characteristic morphologic features and rapid progression of CAD in the second graft were similar to those in the primary graft.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1988        PMID: 3052011     DOI: 10.1016/0002-9149(88)90885-5

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  13 in total

1.  Graft vascular disease in heart transplant patients.

Authors:  J Mann
Journal:  Br Heart J       Date:  1992-09

2.  The risk of coronary artery disease after heart transplantation is increased in patients receiving low-dose cyclosporine, regardless of blood cyclosporine levels.

Authors:  A Gamba; F Mamprin; R Fiocchi; M Senni; G Troise; P Ferrazzi; R Ferrara; G Corbetta
Journal:  Clin Cardiol       Date:  1997-09       Impact factor: 2.882

Review 3.  Cardiac transplantation.

Authors:  H A Valantine; J S Schroeder
Journal:  Intensive Care Med       Date:  1989       Impact factor: 17.440

4.  Combined coronary intervention in heart-transplant patient with rapidly accelerated cardiac allograft vasculopathy.

Authors:  T Koyanagi; S Kyo; H Ouchi; H Asano; Y Yokote; R Omoto
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2001-02

5.  Transplant Coronary Vasculopathy.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2001-02

6.  Accelerated arteriosclerosis in heart transplant recipients is associated with a T-lymphocyte-mediated endothelialitis.

Authors:  R H Hruban; W E Beschorner; W A Baumgartner; S M Augustine; H Ren; B A Reitz; G M Hutchins
Journal:  Am J Pathol       Date:  1990-10       Impact factor: 4.307

7.  Influence of donor and recipient sex mismatch on heart transplant outcomes: analysis of the International Society for Heart and Lung Transplantation Registry.

Authors:  Kiran K Khush; Jessica T Kubo; Manisha Desai
Journal:  J Heart Lung Transplant       Date:  2012-03-13       Impact factor: 10.247

Review 8.  New developments in the diagnosis and management of cardiac allograft vasculopathy.

Authors:  M R Mehra; H O Ventura; F W Smart; D D Stapleton; T J Collins; S R Ramee; J P Murgo; C J White
Journal:  Tex Heart Inst J       Date:  1995

9.  Coronary occlusive disease and late graft failure after cardiac transplantation.

Authors:  P A Mullins; N R Cary; L Sharples; J Scott; D Aravot; S R Large; J Wallwork; P M Schofield
Journal:  Br Heart J       Date:  1992-09

10.  Percutaneous transluminal coronary angioplasty of focal coronary lesions after cardiac transplantation.

Authors:  W von Scheidt; B M Kemkes; B Reichart; E Erdmann
Journal:  Clin Investig       Date:  1993-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.